Nanobiotix is a clinical-stage biotechnology company with a perfect 4-quarter earnings beat streak, rising trading volume, and positive momentum, but the business quality score sits below the minimum investable threshold at 3.5 out of 10, the stock has essentially zero upside to the analyst price target at just 0.5%, and the risk-reward is deeply unfavorable at 0.07.
Thesis pillars
- Quality Below Minimum Threshold↓Deteriorating
- Negligible Upside Poor Risk Reward→Stable
- Perfect Earnings Beat Streak→Stable
- +1 more pillar — see the Why tab for full reasoning
Pillars as of Jul 3, 2026
Nanobiotix S.A. (NBTX) Stock Analysis
Inst Constrain edge
Healthcare · Biotechnology
Sell if holding. Engine safety override at $33.98: Quality below floor (3.2 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.7/10 and A.R:R 2.3:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality.
Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used... Read more
Sell if holding. Engine safety override at $33.98: Quality below floor (3.2 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.7/10 and A.R:R 2.3:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Score 5.7/10, moderate confidence.
Passes 8/8 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 152d clear, semi cycle peak clear, materials cycle peak clear). Suitability: speculative.
Recent developments
updated 2026-10-29Recent Developments — Nanobiotix S.A.
Latest news
- NEWS Nanobiotix Announced At ESMO Saturday, Phase 1 JNJ-1900 Data Showing 41.7% Response Rate, With 4 Complete Responses, 75% — benzinga Oct 25, 2026 positive
- NEWS Nanobiotix Announces Final Data from Phase 1 Study of JNJ-1900 in Cutaneous Melanoma — fiscal.ai Oct 24, 2026 neutral
- NEWS Healthcare Services Posts Upbeat Q3 Earnings, Joins Pool, Spotify And Other Big Stocks Moving Higher On Thursday — benzinga Oct 22, 2026 neutral
- NEWS Winnebago Industries Posts Upbeat Q4 Earnings, Joins SpaceX, Super Micro Computer And Other Big Stocks Moving Higher On — benzinga Oct 21, 2026 neutral
- NEWS Nanobiotix H1 EPS $(0.82) Down From $(0.12) YoY, Sales $6.533M Down From $30.202M YoY — benzinga Sep 24, 2026 negative
Generated 2026-10-29T12:43:34Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers·1 ceiling hit
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $33.98: Quality below floor (3.2 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.7/10 and A.R:R 2.3:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $31.60. Score 5.7/10, moderate confidence.
Analyst target: $45.82 (+34.8% upside). Prior stop was $31.60. Stop-loss: $31.60.
Quality below floor (3.2 < 4.0).
Nanobiotix S.A. trades at a P/E of N/A (forward -202.6). TrendMatrix value score: 9.0/10. Verdict: Sell.
12 analysts cover NBTX with a consensus score of 4.3/5. Average price target: $54.
What does Nanobiotix S.A. do?Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the...
Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck, liver, prostate, pancreatic, esophageal, rectal, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is based in Paris, France.